gastric electrical stimulation (GES). (Strong recommendation, moderate level of evidence)
Summary of Evidence . Gastroparesis is defi ned as a syndrome of objectively delayed gastric emptying in the absence of mechanical obstruction and cardinal symptoms including early satiety, postprandial fullness, nausea, vomiting, bloating, and upper abdominal pain ( 2 ) ; the same constellation of complaints may be seen with other etiologies, including gastritis secondary to Helicobacter pylori infection, peptic ulcer, and functional dyspepsia. Symptoms have not been well correlated with gastric emptying. Nausea, vomiting, early satiety, and postprandial fullness correlate better with delayed gastric emptying than upper abdominal pain and bloating ( 3, 4 ) . Th e epidemiology and impact of gastroparesis are reviewed elsewhere ( 2 ) . In summary, although a high prevalence of gastroparesis has been reported in type 1 diabetics (40 % ) and type 2 diabetics (10 -20 % ), these studies were from tertiary academic medical centers where the prevalence is expected to be higher than the general population; the community prevalence was estimated to be ~ 5 % among type 1 diabetics, 1 % among type 2 diabetics, and 0.2 % of controls in Olmsted County, Minnesota ( 5 ) . More community-based data are required to confi rm or enhance the published fi gures. Gastroparesis signifi cantly impacts quality of life ( 6, 7 ) , increases direct health-care costs through hospitalizations, emergency room, or doctor visits, and is associated with morbidity and mortality ( 8, 9 ) .
Th e symptoms are oft en the same with the diff erent etiologies of gastroparesis: nausea, vomiting, early satiety, and postprandial fullness ( 10 ) . In 416 patients from the NIH Gastroparesis Registry, symptoms prompting evaluation more oft en included vomiting for diabetic gastroparesis (DG) and abdominal pain for idiopathic gastroparesis (IG). Patients with IG have more early satiety and abdominal pain compared with patients with DG who have more severe retching; all the patients included in these multicenter studies had documentation of delayed gastric emptying in their medical record ( 11, 12 ) .
Abdominal pain is an oft en under-appreciated symptom in gastro paresis. In a multicenter study from an NIH consortium on gastro paresis, 72 % of patients with gastroparesis had abdominal pain, but was the dominant symptom in only 18 % ( 13 ), refl ecting the heterogeneous patient population in this cohort. A tertiary referral study showed that abdominal pain was reported in 90 % of 68 patients with delayed gastric emptying (18 DG and 50 IG) . Pain was induced by eating (72 % ), was nocturnal (74 % ), and interfered with sleep (66 % ). Severity ranking of abdominal pain was in the same range as other symptoms (e.g., fullness, bloating, and nausea) and was not correlated with gastric emptying rate, but was associated with impaired quality of life. Th e preponderance of the idiopathic group and large proportion of daily (43 % ) or even constant pain (38 % ) in this cohort of patients may refl ect the type of referred patients oft en seen in tertiary academic centers ( 12 ) . Th e presence of anxiety or depression has been associated with more severe symptoms ( 14, 15 ) . Th e combination of symptoms and delayed gastric emptying is required to establish the diagnosis of gastroparesis as the epidemiology, natural history, pathophysiology, and treatment of gastroparesis (which are reviewed in detail elsewhere ( 2 ) ) are typically based on combined criteria. Diabetes with evidence of gastroparesis on objective testing has been associated with increased health-care costs, including increased clinic visits, emergency room visits, hospitalizations, overall morbidity and mortality ( 8, 9 ) .
Since accelerated gastric emptying and functional dyspepsia can also present with symptoms similar to gastroparesis, documentation of delayed gastric emptying ( 3, 16 ) is necessary before selecting therapy with prokinetics agents or GES. Serious ( − 1) or very serious ( − 2) limitation to study quality Important inconsistency ( − 1) Some ( − 1) or major ( − 2) uncertainty about directness Imprecise or sparse data ( − 1) High probability of reporting bias ( − 1)
IDENTIFYING THE CAUSE OF GASTROPARESIS

Increase grade if:
Strong evidence of association -signifi cant relative risk of > 2 ( < 0.5) based on consistent evidence from two or more observational studies, with no plausible confounders ( + 1)
Very strong evidence of association -signifi cant relative risk of > 5 ( < 0.2) based on direct evidence with no major threats to validity ( + 2)
Evidence of a dose response gradient ( + 1)
All plausible confounders would have reduced the effect ( + 1)
Defi nitions of grades of evidence High = Further research is unlikely to change our confi dence in the estimate of effect
Moderate =Further research is likely to have an important impact on our confi dence in the estimate of effect and may change the estimate Low =Further research is very likely to have an important impact on our confi dence in the estimate of effect and is likely to change the estimate Very low =Any estimate of effect is very uncertain experiencing resolution of symptoms, these individuals note persistent nausea, vomiting, and early satiety. Over a period of about a year, the gastroparesis oft en improves. In general, this course is typical of postviral gastroparesis that is not associated with autonomic neuropathy. On the other hand, a minority of patients with infections due to viruses such as cytomegalovirus, EpsteinBarr virus, and varicella zoster may develop a form of autonomic neuropathy (generalized or selective cholinergic dysautonomia) that includes gastroparesis. Th ese patients with autonomic dysfunction may have slower resolution of their symptoms that may take several years and the prognosis is worse than in postviral gastroparesis without autonomic disorders ( 20, 21 ) . Postsurgical gastroparesis (PSG) , oft en with vagotomy or vagus nerve injury, represents the third most common etiology of gastroparesis. In the past, most cases resulted from vagotomy performed in combination with gastric drainage to correct medically refractory or complicated peptic ulcer disease. Since the advent of laparoscopic techniques for the treatment of GERD, gastroparesis has become a recognized complication of fundoplication (possibly from vagal injury during the surgery) or bariatric surgery that involves gastroplasty or bypass procedures. Th e combination of vagotomy, distal gastric resection, and Roux-en-Y gastrojejunostomy predisposes to slow emptying from the gastric remnant and delayed transit in the denervated Roux eff erent limb. Th e Roux-en-Y stasis syndrome -characterized by postprandial abdominal pain, bloating, nausea, and vomiting -is particularly diffi cult to manage, and its severity may be proportional to the length of the Roux limb (generally, 25 cm is ideal to avoid stasis).
Th e precise role of the antirefl ux surgery itself is not clearly demonstrated in the published literature. Th us, while symptoms suggesting gastric stasis are extremely common in the fi rst 3 months aft er fundoplication, they persist in a minority of patients at 1 year post surgery. In a series of 615 patients who underwent laparoscopic Nissen fundoplication, all had symptoms during the fi rst 3 postoperative months (e.g., early satiety in 88 % and bloating / fl atulence in 64 % ); however, by 1 year these symptoms suggestive of gastroparesis like bloating / fl atulence had resolved in > 90 % of patients ( 22 ) . Moreover, among 81 patients with antirefl ux operations followed for > 1 year, the fi nding of postoperative symptoms suggesting delayed gastric emptying was usually associated with delayed gastric emptying pre-operatively ( 23 ) . Th e precise role of fundoplication is therefore diffi cult to determine unless the patient undergoes testing for abdominal vagal dysfunction, such as the plasma pancreatic polypeptide response to modifi ed sham feeding; such tests are described elsewhere ( 24 ) .
In patients with refractory symptoms of GERD , investigation for delayed gastric emptying should be considered, since delayed gastric emptying can be associated with GERD and possibly aggravate symptoms of heartburn, regurgitation, and other symptoms associated with GERD.
Known causes of iatrogenic gastroparesis include surgical vagal disruption, which may be due to vagal nerve injury (e.g., aft er fundoplication for GERD), or intentional vagotomy as part of peptic ulcer surgery. Th e second major category of iatro genic gastro paresis is induced by pharmacological agents as may Summary of Evidence . Diabetic (29 % ), postsurgical (13 % ), and idiopathic (36 % ) etiologies comprise the majority of cases in tertiary referral setting ( 8 ) . Diabetes mellitus is the most commonly recognized systemic disease associated with gastroparesis. In the NIH consortium cohort, delayed gastric emptying was more pronounced in patients with type 1 DG (10). Th e 10-year incidence of gastroparesis has been reported to be 5.2 % in type 1 diabetes, 1 % in type 2 diabetes, and 0.2 % in non-diabetic controls in a US community ( 5 ) .
Idiopathic gastroparesis refers to a symptomatic patient from delayed gastric empting with no detectable primary underlying abnormality for the delayed gastric emptying. Th is may represent the most common form of gastroparesis ( 10, 17 ) . Most patients with IG are women; typically young or middle aged. Symptoms of IG overlap with those of functional dyspepsia; it may be diffi cult to provide a defi nitive distinction between the two based on symptoms, and many regard IG and functional dyspepsia with delayed gastric emptying as the same condition. Abdominal pain / discomfort typically is the predominant symptom in functional dyspepsia, whereas nausea, vomiting, early satiety, and bloating predominate in IG. Th erefore, measurement of gastric emptying is important, as therapies diff er if gastric emptying is delayed, normal, or rapid.
A subset of patients with gastroparesis report sudden onset of symptoms aft er a viral prodrome, suggesting a potential viral etiology for their symptoms, and the diagnosis of postviral gastroparesis ( 18, 19 ) . Previously, healthy subjects have developed the sudden onset of nausea, vomiting, diarrhea, fever, and cramps suggestive of a systemic viral infection. However, instead of occur with narcotic opiate analgesics, anticholinergic agents, and some diabetic medications. Administration of μ -opiate receptor agonists results in delayed gastric emptying and also may cause nausea and vomiting. Th ese include agents such as morphine ( 25 ) , as well as oxycodone and tapentadol ( 26 ) , but less with tramadol ( 27 ) . Th erefore, patients receiving such agents should fi rst undergo withdrawal of the agent before assuming a diagnosis of gastroparesis. GLP-1 analogs, such as exenatide, used for treatment of type 2 diabetes mellitus ( 28 ) can delay gastric emptying. In contrast to GLP-1 analogs, which substantially increase plasma GLP-1 concentrations, dipeptidyl peptidase IV inhibitors, which increase plasma GLP-1 concentrations by inhibiting metabolism of GLP-1, do not delay gastric emptying ( 29 ) . Nausea (43.5 % ) was the most commonly reported adverse event with exenatide treatment, and vomiting was also quite commonly encountered (12.8 % ( 30 ) ). Th e antirejection drug, cyclosporine, can delay gastric emptying. Th us, in patients with prior pancreatic transplantation treated with antirejection treatment with cyclosporine, there may be delay in gastric emptying ( 31 ) . Th is does not apply to another calcineurin inhibitor, tacrolimus, which is derived from a macrolide molecule and retains prokinetic properties ( 32 ) .
Other rarer causes of gastroparesis include diseases aff ecting the extrinsic neural control (such as Parkinsonism, amyloidosis, and paraneoplastic disease) or disorders that result in infi ltration or degeneration of the muscle layer of the stomach (such as scleroderma). Mesenteric ischemia should also be considered as a rare cause of gastroparesis that is potentially reversible. ( 34 ) . Assessment of gastric emptying over 4 h is necessary ( 35 ) . Shorter duration solid emptying or sole liquid emptying by scintigraphy is associated with lower diagnostic sensitivity. Measurement of liquid gastric emptying, simultaneously or in addition to solid emptying, has been advocated as a means of increasing sensitivity (by an estimated 25 -36 % in non-diabetics) to detect the presence of gastro paresis in patients with upper gastrointestinal (GI) symptoms ( 36, 37 ) . On the other hand, the clinical signifi cance of selectively delayed gastric emptying of liquids has not been assessed, for example, in terms of its value in predicting response of symptoms to treatment. Th ere is evidence that the eff ect of hyperglycemia on gastric emptying in diabetics is more clearly demonstrated in the retardation of the gastric emptying of liquids ( 38 ) .
DIAGNOSIS OF GASTROPARESIS
Th e most reliable parameter to report gastric emptying is the gastric retention at 4 h. Gastric emptying T 1 / 2 is also acceptable if imaging has been performed for 4 h or at least to 50 % emptying, as extrapolation to measure t 1 / 2 may be erroneous. However, it is also important to assess emptying at least 1 and 2 h aft er radiolabeled meal ingestion, since prolongation of the early phases of emptying may also be associated with symptoms of gastroparesis, even though the gastric retention at 4 h is normal or mildly delayed. Gastric emptying T 1 / 2 can be quite easily inferred from the linear interpolation of the data points at 1, 2, and 4 h, since the emptying phase of solids is generally linear aft er the initial lag phase and gastroparesis due to neuropathic or myopathic motility disorders retards gastric emptying T 1 / 2 ( 39 -41 ) .
A WMC that measures pH, pressure, and temperature can assess gastric emptying by the acidic gastric residence time of the capsule. Gastric emptying is determined when there is a rapid increase in contraction with lower esophageal sphincter relaxation in the early postprandial period is responsible for regurgitation. Typically, the eff ortless repetitive regurgitation occurs within 15 min of starting a meal, in contrast to vomiting from gastroparesis, which occurs later in the postprandial period.
Eating disorders, such as anorexia and bulimia, can present with similar presentations. Anorexia nervosa is a psychiatric disorder occurring primarily in adolescent and young adult women characterized by distorted body image and fear of obesity with compulsive dieting and self-imposed starvation to maintain a profoundly low body weight. GI symptoms are common and include lack of appetite, early satiety, epigastric fullness, abdominal bloating, nausea, and vomiting. Th e loss of body weight seen in eating disorders can cause a compensatory delay in gastric emptying. Interestingly, re-alimentation and maintenance of normal body weight improve gastric emptying and GI symptoms, but do not totally normalize them (reviewed in ref. ( 48 )).
Bulimia nervosa is characterized by recurrent episodes of binge eating with a feeling of lack of control over the eating behavior during the binges, oft en followed by self-induced vomiting, the use of laxatives or diuretics, strict dieting or fasting, or vigorous exercise to prevent weight gain. Gastric emptying studies in bulimia have yielded confl icting results ( 49 -51 ) .
CVS or episodic vomiting episodes are becoming more frequently diagnosed in adults ( 52 ) . CVS refers to recurrent episodes of intense nausea and vomiting lasting hours to days separated by symptom-free periods of variable lengths. Typically, each episode is similar. Vomiting oft en starts abruptly, although a prodrome of nausea and abdominal pain can occur. In adults, as compared to children with CVS, the vomiting episodes are longer (3 -5 days), less frequent (every 3 -4 months), and triggering events are less evident; there is usually a long delay in diagnosis. Gastric emptying has been reported to be rapid in the symptom-free period. When the episodes of vomiting become closer together, diff erentiation of " coalescent " CVS from the more typical daily symptoms of gastroparesis in an adult can be challenging. New data on the prevalence of gastric stasis in migraine off er the potential for a better understanding of the mechanisms of CVS. Typically, gastric emptying in CVS is normal or rapid; however, 14 % of a large series of patients had delayed gastric emptying ( 53 ) . the pH recorded indicating emptying from the acidic stomach to the alkaline duodenum. Th e gastric residence time of the WMC (e.g., SmartPill, Given Imaging, Yoqneam, Israel) had a high correlation 85 % with the T-90 % of gastric emptying scintigraphy (that is the time when there was only 10 % of the meal remaining in the stomach), suggesting that the gastric residence time of the WMC represents a time near the end of the emptying of a solid meal ( 42 ) . Th e overall correlation between gastric emptying time of the WMC and gastric emptying at 4 h by scintigraphy was 0.73. A 5-h gastric residence time of the WMC was best to diff erentiate subjects with delayed or normal gastric emptying based on scintigraphy conducted simultaneously with sensitivity of 83 % and specifi city of 83 % . Breath testing has been used in both clinical and clinical research studies for determining gastric emptying ( 43 ) . Th ese breath tests using 13 C-octanoate or -spirulina ( 44 ) provide reproducible results that correlate with results on gastric emptying scintigraphy, including responsiveness to pharmacological therapy. Th e optimization of mathematical models for measurement of gastric emptying derived from breath excretion profi les has been thoroughly examined in the literature ( 45 ) . Both WMC and breath testing require further validation before they can be considered as alternates to scintigraphy for diagnosis of gastroparesis. Summary of Evidence . Th e vomiting symptom of a patient can be diffi cult to diff erentiate from the regurgitation seen in GERD or the regurgitation seen in rumination syndrome . Rumination syndrome is a condition characterized by the repetitive, eff ortless regurgitation of recently ingested food into the mouth followed by re-chewing and re-swallowing or expectorating of food. Although initially described in infants and the developmentally disabled, rumination syndrome is now widely recognized at all ages and cognitive abilities; the condition is more frequent in females, but it is recognized in adolescent and adult males ( 46, 47 
MANAGEMENT OF GASTROPARESIS
EXCLUSION CRITERIA AND DIFFERENTIAL DIAGNOSIS
Summary of Evidence . Diet and Nutritional Support
Gastroparesis can lead to poor oral intake, a calorie-defi cient diet, and defi ciencies in vitamins and minerals ( 54, 55 ) . Th e choice of nutritional support depends on the severity of disease. In mild disease, maintaining oral nutrition is the goal of therapy. In severe gastroparesis, enteral or parenteral nutrition may be needed. For oral intake, dietary recommendations rely on measures that optimize gastric emptying such as incorporating a diet consisting of small meals that are low in fat and fi ber. Since gastric emptying of liquids is oft en preserved in gastroparesis, blenderized solids or nutrient liquids may empty normally. Th e rationale of this approach is not validated by controlled studies, but mainly derived from an empirical approach.
Oral Nutrition Meals with low-fat content and with low residue should be recommended for gastroparesis patients, since both fat and fi ber tend to delay gastric emptying. Small meal size is advisable because the stomach may only empty an ~ 1 -2 kcal / min. Th erefore, small, lowfat, low-fi ber meals, 4 -5 times a day, are appropriate for patients with gastroparesis. Increasing the liquid nutrient component of a meal should be advocated, as gastric emptying of liquids is oft en normal in patients with delayed emptying for solids ( 56, 57 ) . Poor tolerance of a liquid diet is predictive of poor outcome with oral nutrition ( 57 ) . High calorie liquids in small volumes can deliver energy and nutrients without exacerbating symptoms. Th e caloric requirement of a patient can be calculated by multiplying 25 kcal by their current body weight in kilograms ( 58 ) . In some patients, carbonated beverages, with release of carbon dioxide, can aggravate gastric distension; their intake should be minimized ( 56 ) . Alcohol and tobacco smoking should be avoided because both can modify gastric emptying ( 59 -61 ) . In diabetics, near normal glycemic control with diet and hypoglycemic drugs should be aimed for, as improvement of hyperglycemia can accelerate gastric emptying.
Enteral Nutrition For patients with gastroparesis who are unable to maintain nutrition with oral intake, a feeding jejunostomy tube, which bypasses the aff ected stomach, can improve symptoms and reduce hospitalizations ( 62 ). Placement of a jejunal feeding tube, if needed for alimentation, should be preceded by a successful trial of nasojejunal feeding. Occasionally, small bowel dysfunction may occur in patients with gastroparesis leading to intolerance to jejunal feeding.
Usefulness and disadvantages of diff erent forms of intubation are summarized in Table 2 . In appropriate patients with normal small bowel function, jejunal feeding maintains nutrition, relieves symptoms, and reduces the frequency of hospital admissions for acute exacerbation of symptoms ( 64 ) . Small intestinal motility / transit can be assessed before placement of jejunostomy tube with antroduodenojejunal manometry, WMC, and small intestinal transit scintigraphy. Given the large coeffi cient of variation of small bowel transit time, and the diffi culty in interpretation of orocecal transit measurements in the setting of gastroparesis, a practical way to assess small bowel function is by a trial of nasojejunal feeding. Nutrient feeds are started with diluted infusions and advanced gradually to iso-osmolar preparations at relatively low infusion rates (e.g., 20 ml / h) increasing to the target infusion rate to support nutrition and hydration typically to at least 60 ml / h over 12 -15 h / day. Regu lated enteral nutrition may improve glycemic control in diabetic patients with recurrent vomiting and unpredictable oral intake. Complications include infection, tube migration, and dislodgement ( 65 ) . Such nutritional support may also be eff ective in patients with systemic sclerosis with signifi cant malnutrition, and lead to restoration of adequate nutritional status, improved quality of life, and few metabolic or technical complications over a period of 12 -86 months ( 66 ) . Th ere is a theoretical risk of increased pulmonary aspiration in patients with weak lower esophageal sphincter; hence, it is advisable that the feeding tube should be placed well beyond the angle of Treitz in such patients.
Enteral feeding should always be preferred over parenteral nutrition for a wide range of practical reasons, such as costs, potential for complications, and ease of delivery. Acute hyperglycemia induced in experimental clinical studies has been shown to worsen gastric emptying or inhibit antral contractility, though the relationship to symptoms is unclear. Th e effi cacy of long-term improvement in glycemic control on normalization of gastric emptying and relief of symptoms in diabetic patients is controversial. Nevertheless, short-and long-term glycemic control is indicated for improved long-term outcome of diabetes. Attempts to normalize glycemic control using amylin analogs (e.g., pramlintide) or GLP-1 analogs (e.g., exenatide) may result in delayed gastric emptying ( 75, 76 ) . In contrast, dipeptidyl peptidase IV inhibitors (e.g., sitagliptin and vildagliptin ( 29 )) do not delay gastric emptying. Summary of Evidence . Th e evidence for use of current prokinetics is based on trials performed two or three decades ago. Th erefore, the level of evidence is not based on the currently suggested rigorous, large trials with validated patient response outcomes measured on a daily basis. Current trials include the daily diary Gastroparesis Cardinal Symptom Index ( 77 ) and a validated instrument to assess quality of life specifi c for upper GI disorders, the Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life ( 78 )); however, there are no full manuscripts published using such instruments and the recent institution of patient reported outcome requirements at the FDA may result in modifi cation of this and other diaries. Metoclopramide , a dopamine D2-receptor antagonist, is the only US FDA-approved medication for the treatment of gastroparesis for no longer than a 12-week period ( 79 ), unless patients have therapeutic benefi t that outweighs the potential for risk. Metoclopramide is available in several formulations including oral dissolution tablet, oral tablet, liquid formulation, and parenteral formulation. Th e latter may be administered IV, by intramuscular injection, or subcutaneously ( 80 ) . Th e FDA placed a black-box warning on metoclopramide because of the risk of side eff ects, including tardive dyskinesia. Th e most common adverse extrapyramidal side eff ects of metoclopramide are acute dystonias (incidence of 0.2 % ( 81 )). Th e incidence of acute dystonias in a UK series was higher in females, patients receiving higher doses, in children, and young adults. Whereas prolonged reactions were more common in elderly patients. About 95 % of metoclopramide-induced involuntary movements reported over 15 years were dystonias, 4 % parkinsonism type movements, and 1 % tardive dyskinesia ( 82 ) . Involuntary movements may be more likely with parenteral administration ( 83 ) . Th e dystonic reactions may be reversed with antihistamines (e.g., diphenhydramine 25 -50 mg IV administered over 2 min), benzodiazepines (e.g., diazepam 5 -10 mg IV) or centrally acting anticholinergic agents (e.g., benztropine 1 -4 mg IV up to 6 mg / day). Metoclopramide can also be associated with corrected QT interval prolongation.
GLYCEMIC CONTROL IN DG
Th e effi cacy of metoclopramide in the treatment of DG has been assessed in four placebo-controlled trials, two active comparatorcontrolled and open-label studies that are summarized in Table 4 . In summary, symptoms improved in fi ve studies in which the primary objective was clinical; gastric emptying was accelerated in all studies in which it was appraised. None of the trials was conducted for > 4 weeks, and longer term effi cacy is unproven and limited to openlabel experience in small numbers of patients ( 92 ) . Recommendations on when and how to use metoclopramide for the treatment of gastroparesis in clinical practice have been published ( 93 ) and include careful monitoring of the patient for earliest signs of tardive dyskinesia (which may be reversible with early recognition and cessation of therapy), use of the lowest eff ective dose for each patient, starting at 5 mg t.i.d. before meals, use of the liquid formulation to improve absorption and facilitate dose titration to a maximum dose of 40 mg / day and use of " drug holidays " or dose reductions (e.g., 5 mg, before two main meals of the day) whenever clinically possible. Drug -drug interactions may occur with concomitant administration of drugs that alter cytochrome P450-2D6 (CYP2D6) function ( 94 ) .
Domperidone is a type II dopamine antagonist similar to metoclopramide, and is equally effi cacious but with lower central side eff ects. It is available for use under a special program administered by the FDA and via other pathways. Table 5 summarizes the full articles of clinical trials with domperidone; this drug is generally as eff ective as metoclopramide with main effi cacy on nausea and vomiting and lower risk of adverse eff ects than with metoclopramide. Th e starting dose is 10 mg t.i.d. increasing to 20 mg t.i.d. and at bedtime. Given the propensity of domperidone to prolong corrected QT interval on electrocardiogram and to rarely cause cardiac arrhythmias, a baseline electrocardiogram is recommended and treatment with this agent should be withheld if the corrected QT is > 470 ms in male and over 450 ms in female patients. Follow-up electrocardiogram on domperidone is also advised to check for prolongation of the corrected QT interval. Domperidone may also cause increased prolactin levels and result in lactation; drug -drug interactions may occur with concomitant administration of drugs that alter CYP2D6 function ( 106 ) . Drugs that infl uence CYP2D6 include antiemetics and antidepressants that are frequently co-administered in patients with gastroparesis.
Erythromycin lactobionate is eff ective when given IV at a dose of 3 mg / kg every 8 h (by IV infusion over 45 min to avoid sclerosing veins), as was shown in hospitalized diabetics with gastroparesis ( 107 ) . Many motilin agonists, including erythromycin, when given orally may also improve gastric emptying and symptoms for several weeks, but over longer periods are oft en associated with tachyphylaxis due to downregulation of the motilin receptor. Clinical responsiveness drops aft er 4 weeks of oral erythromycin agents (including promethazine). Several US medical centers have recently placed several additional restrictions on promethazine, related to concerns about sedation, possible cardiac toxicity (corrected QT prolongation ( 110 )), damage to peripheral veins, and lack of availability of the drug ( 111 ). Th ere are no studies that compare effi cacy of phenothiazines with newer antiemetics (such as serotonin 5-HT 3 -receptor antagonists) for gastroparesis. Th ere is no evidence that ondansetron is superior to metoclopramide and promethazine in reducing nausea in adults attending an emer gency department ( 112 ). 5-HT 3 -receptor antagonists are reasonable second-line medications; the neurokinin receptor-1 antagonist, aprepitant, was eff ective in treatment of severe vomiting and repeated episodes of ketoacidosis in a patient with diabetes ( 113 ) .
Th e synthetic cannabinoid, dronabinol, is also used in practice, but there is risk of hyperemesis on withdrawal ( 114 ), and optimum treatment strategies are unclear. Transdermal scopolamine, which is eff ective for nausea associated with motion sickness, is used for nausea and vomiting of gastroparesis, albeit without peer-reviewed publications to support this practice. Among alternative medicine therapies, acupuncture is the method most studied in treatment of nausea and vomiting; one study reported impressive relief in 94 % of patients ( 115 ) (see section on alternative medicine).
TCA can be considered for refractory nausea and vomiting in gastroparesis ( 116, 117 ) . Th e management of pain remains a challenge, which has not been addressed in clinical trials of patients with gastroparesis. Agents used in practice are not based on evidence of effi cacy for pain. TCA and selective serotonin reuptake inhibitors are eff ective for depression in diabetes, and this is associated with improved glycemic control and physical symptoms ( 118,119 ). Open-label treatment studies have reported that ( 108 ) ; however, some patients may continue to experience benefi t. Erythromycin is also subject to drug interactions with agents that alter or are metabolized by CYP3A4. Administration of erythromycin can also be associated with the development of corrected QT prolongation.
Metoclopramide and erythromycin are available in liquid form. In healthy volunteers, an orally disintegrating tablet was bioequivalent to a conventional tablet. In healthy volunteers, single administration of 10-mg metoclopramide orally disintegrating tablet (ODT) was well tolerated and bioequivalent to single administration of a conventional 10-mg metoclopramide tablet ( 109 ) . It is possible that their pharmacokinetic profi les will be enhanced relative to tablet formulation in patients with gastroparesis; however, this has not been demonstrated in trials in patients. In patients with gastroparesis, liquid formulation is less likely to accumulate in the stomach in contrast to tablets, which may require more eff ective gastric motility to empty from the stomach; such erratic emptying may conceivably lead to several retained tablets being emptied together and lead to high plasma levels aft er absorption, potentially causing adverse events. Another potential advantage of the liquid formulation is that it allows for easier dose titration. For these reasons, a recent review recommended use of the liquid formula of metoclopramide in patients with severe gastroparesis ( 93 ) .
Symptomatic Treatment of Nausea, Vomiting, and Pain in Gastroparesis Syndrome. Other than prokinetics, the symptomatic treatment of these symptoms remains empirical and off -label use of these drugs from the indications for non-specifi c nausea and vomiting, or chemotherapy-induced emesis and palliative care. Th e most commonly prescribed antiemetic drugs are the phenothiazines (including prochlorperazine and thiethylperazine) or antihistamine TCA in low doses may decrease symptoms of nausea, vomiting, and abdominal pain in DG and IG ( 116, 117 ) . However, some tricyclic agents, such as amitriptyline, have anticholinergic eff ects and should be avoided in patients with gastroparesis, as they delay gastric emptying. Nortriptyline has lower incidence of anticholinergic side eff ects than amitriptyline. Th e 5-HT 2 receptor antagonist, mirtazapine, has been reported effi cacious in a single report in gastroparesis ( 120 ) . For patients taking narcotic opiate analgesics, these narcotics should be stopped, if possible, as these agents worsen gastric emptying and may themselves induce symptoms of nausea and vomiting. In addition, chronic use may be associated with increasing abdominal pain. Tramadol, tapentadol, gabapentin, pregabalin, and nortriptyline may be alternatives for pain; however, their eff ect on gastric emptying is still unclear. Th e μ -opioid receptor agonist, tramadol (which also releases serotonin and inhibits the reuptake of norepinephrine), is also used. In one study ( 27 ) , it did not delay gastric emptying, though it signifi cantly delayed colonic transit in healthy volunteers. No data are available in patients with gastroparesis. Both the related compound, tapentadol, and the more selective μ -opioid receptor agonist, oxycodone, are reported to retard gastric emptying in healthy subjects ( 26 ) .
INTRAPYLORIC BOTULINUM TOXIN INJECTION
Recommendations
Intrapyloric injection of botulinum toxin is not recommended for patients with gastroparesis based on randomized controlled trials. (Strong recommendation, high level of evidence.)
Summary of Evidence . Manometric studies of patients with DG
show prolonged periods of increased pyloric tone and phasic contractions, a phenomenon termed as " pylorospasm. " Botulinum toxin is a potent inhibitor of neuromuscular transmission. Several open-label studies in small numbers of patients with DG and IG lower energy electrical stimulation to the stomach. Th e device was approved by the FDA as a humanitarian device exemption in patients with refractory symptoms of gastroparesis of diabetic or idiopathic etiology in 2000 based on two studies ( 158 ) . Th e fi rst, an open-labeled study showed improvement in both specifi c and global gastroparesis symptoms and gastric emptying ( 137 ) . Th e second, a double-blind, randomized, crossover study reported improvement of weekly vomiting frequency (WVF) and quality of life in DG and in the whole patient cohort, but not in the IG subgroup. Th e study sample size enrolled only about 50 % of what had originally been planned and was underpowered ( 159 ) . Most subsequent reports have been open-label studies, including long-term effi cacy reports of several hundred patients, suggesting that GES enhances symptom control and quality of life and improves oral tolerance of feeding ( 155 ) . An initial meta-analysis ( 157 ) suggested substantial benefi ts for gastroparesis, but identifi ed that, among 13 included studies, 12 lacked controls and only 1 was blinded and randomized. A more recent meta-analysis on GES showed similar results and identifi ed DG patients as the most responsive to GES, both subjectively and objectively, while the IG and PSG subgroups were less responsive ( 160 ). Both meta-analyses observed mild improvements in gastric emptying and modest in symptoms for several months (see Table 6 ). Two double-blind, placebo-controlled studies have shown some improvement in gastric emptying, but no improvement in symptoms compared with placebo ( 131, 135 ) . Th us, botulinum toxin injection into the pylorus is not recommended as a treatment for gastroparesis ( 134 ) , although there is a need for further study in patients with documented " pylorospasm. " Summary of evidence . GES delivers high frequency ( Table 7 ) (several fold higher than the intrinsic gastric electrical frequency), Clinical Guideline: Management of Gastroparesis Reduced GI symptoms, and improved HRQOL; 90 % had response in at least one of three main symptoms Improved Pocket infections, later re-implanted successfully; no deaths directly related to the device Table 7 continued on following page gastroparesis), in which all patients had the devices on for several weeks before the randomization occurred, showed no signifi cant diff erence in WVF between on vs. off periods during the subsequent crossover period ( 161 ) . However, at 1 year post implant, when all patients had the device switched on, the WVF remained and review of the literature indicate that further controlled studies are required to confi rm the clinical benefi ts of highfrequency GES. A multicenter, randomized, controlled study involving 55 patients with DG (mean age 38 years, 66 % female, average 5.9 years of AEs, adverse effects; BMI, body mass index; CIP, chronic intestinal pseudo-obstruction; DG, diabetic gastroparesis; DM, diabetic; GCSI, gastroparesis cardinal symptom index; GE, gastric emptying; GES, gastric electrical stimulation; GI, gastrointestinal; GSRS, gastrointestinal symptom rating scale; HRQOL, health-related quality of life; N, nausea; ND, not done; PS, postsurgical; QOL, quality of life; TPN, total parenteral nutrition; TSS, total symptom score; V, vomiting. Reproduced in part from ref. ( 157 ) . N reports patients recruited into each study; outcomes were often available on fewer patients.
GASTRIC ELECTRICAL STIMULATION
Clinical Guideline: Management of Gastroparesis lower than baseline (median reduction of WVF of 67.8 % , P < 0.001), refl ecting the previously reported open-label experience. Similar reports have been recorded in IG ( 162 ) . More recent data ( 153 ) have shown eff ects of GES on GI symptoms in as little as 72 h of stimulation, suggesting rapid eff ect of GES on gastric motor activity. In this study, aft er a temporary endoscopic lead was implanted for a trial of high-frequency / lowenergy GES using an external device, patients were randomized to either on / off or off / on at baseline. Although temporary endoscopic placement of stimulation leads in the stomach may predict response to the permanent device ( 153 ) , this proposal needs further studies to support this practice. In summary, the data presented in Table 7 show that open-label treatment is associated with symptomatic improvement, particularly WVF, and a propensity to cessation of special methods to provide nutrition (such as enteral or parenteral nutrition). Improvement in gastric emptying has been variable. Complications from the device such as local infection or lead migration, as well as complications related to the surgery may occur in up to 10 % of patients implanted. In general, effi cacy for symptomatic improvement appears to be greater for DG than for IG. Th ere is no consensus or societal guideline on the selection of patients (e.g., failed therapeutic trials, or level of nutritional compromise) for the use of GES as compassionate treatment. In an open-label study, patients experienced marked symptomatic improvement, weight was maintained, and total symptom score was reduced up to 3 years post venting gastrostomy ( 165 ) . It is assumed that the same benefi cial outcome occurs with percutaneous endoscopic gastrostomy, though this is not proven.
Several types of surgical interventions have been tried for treatment of gastroparesis: gastrojejunostomy, pyloromyotomy, and completion or subtotal gastrectomy. A recent study reported on a series of 28 patients with gastroparesis in whom pyloroplasty resulted in symptom improvement, with signifi cant improvement in gastric emptying and reduction in the need for prokinetic therapy when followed at 3 months post surgery ( 166 ) . It is unclear whether the effi cacy of pyloroplasty depends on the residual antral motor function; thus, in the few diabetics included in the series, there was no signifi cant improvement in gastric emptying ( 166 ) , and further studies with longer followup are needed to determine overall effi cacy and optimal candidates for pyloroplasty to treat gastroparesis. Completion or subtotal gastrectomy was applied most oft en for gastroparesis that followed gastric surgery for peptic ulcer disease ( 167, 168 ) ; experience from tertiary referral centers suggests that, in carefully selected patients, major gastric surgery can relieve distressing vomiting from severe gastroparesis and improve quality of life ( 169, 170 ) in seriously aff ected patients where risk of subsequent renal failure is high and where life expectancy is poor. Th e risk of malnutrition and weight loss following gastrectomy has to be weighed relative to the symptom relief. Th e use of completion or subtotal gastrectomy in patients with intact gastroparetic stomachs has not been favorable. Pyloroplasty may relieve symptoms in gastroparesis and is oft en combined with operative jejunal tube placement to support nutrition ( 166, 171 ) . Subtotal gastrectomy with Roux-Y reconstruction may be needed for gastric atony secondary to PSG ( 167 ) . In patients undergoing surgical treatment for gastroparesis, a full-thickness gastric biopsy may be helpful to assess the pathologic basis associated with the patient ' s gastroparesis ( 172 -175 ) .
COMPLEMENTARY AND ALTERNATIVE MEDICINES
Recommendations
Acupuncture can be considered as an alternative therapy. Th is has been associated with improved rates of gastric emptying and reduction of symptoms. (Conditional recommendation, low level of evidence)
Summary of evidence . As with many chronic conditions that are poorly understood, patients may search for alternative therapies. Th ese can include: dietary manipulations, physical retraining modalities (autogenic retraining such as that developed by NASA for space motion sickness), and therapies such as acupuncture. Dietary manipulations have been discussed above. Th e use of autonomic retraining in the one series using NASA technology showed that patients with more intact autonomic nervous system activity responded better than patients whose autonomic function was more impaired ( 176 ) .
Other therapies, such as acupuncture, have been tried in a more systematic way than other alternative therapies of gastroparesis. Several recent studies, including one single-blinded, randomized pilot study with sham treatment control, have demonstrated that acupuncture may be of benefi t in gastroparesis ( 177 ) . Th is study of
A prodrome suggesting a viral illness may lead to gastroparesis (postviral gastroparesis). Th is condition may improve over time in some patients. Clinicians should inquire about the presence
19 patients with type 2 diabetics was conducted for 2 weeks with 2 week follow-up: symptom severity (Gastroparesis Cardinal Symptom Index) and, particularly, the postprandial fullness and early satiety and bloating subscales were reduced at end of treatment and end of follow-up. Gastric emptying of solids was shortened with active electroacupuncture relative to baseline; however, gastric emptying times in the active and sham-controlled arms were not well matched at baseline ( 177 ) . Further studies are needed to assess clinical benefi t of acupuncture and other complementary and alternative treatments in patients with gastroparesis. Figure 1 demonstrates a stepwise approach to management of gastroparesis based on these recommendations. An algorithm for management is shown in Figure 2 , and suggestions for prokinetic dosing are outlined in Figure 3 . Clearly, there are specifi c refi nements to this approach based on individual diff erences: Degree of nutritional defi ciency or weight loss, degree of impairment of gastric emptying (or gastric retention at 4 h), and response to earlier " steps " in the management. 
Summary of recommendations .
SUMMARY OF RECOMMENDATIONS
Suspected gastroparesis
Step 1: Diagnosis: 4 h Gastric emptying by scintigraphy
Step 2: Exclude iatrogenic disease
Step 3: Pharmacological Rx:
• Prokinetics: metoclopramide, erythromycin, domperidone • Antiemetics: anti-histamine 1 receptors; 5-HT 3 antagonists
Step 4: Nutritional support: Enternal formula
Step 5: Non-pharmacological Rx 
